Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Poewe

Showing results (231-240 of 258) with videos related to

Pageof 26
Sort By:
European Journal of Neurology|October 14, 2006
Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's diseaseM Horstink, E Tolosa, U Bonuccelli, et al.
Der Nervenarzt|February 10, 2015
[Predictors of mental and physical quality of life in Huntington's disease]F Brugger, C Hepperger, E-M Hametner, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 22, 1998
What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study GroupW Poewe, G Deuschl, A Nebe, et al.
European Journal of Neurology|October 14, 2006
Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's diseaseM Horstink, E Tolosa, U Bonuccelli, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 7, 1998
Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examinationG K Wenning, I Litvan, J Jankovic, et al.
Stroke|October 7, 2000
A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after strokeA M Bakheit, A F Thilmann, A B Ward, et al.
Journal of Neurochemistry|August 25, 2001
Temporal and spatial profile of caspase 8 expression and proteolysis after experimental traumatic brain injuryR Beer, G Franz, S Krajewski, et al.
Parkinsonism & Related Disorders|November 29, 2016
Sniffing the diagnosis: Olfactory testing in neurodegenerative parkinsonismF Krismer, B Pinter, C Mueller, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 16, 2000
Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging studyN Hyman, M Barnes, B Bhakta, et al.
Neurology|January 4, 2007
Recanalization after thrombolysis in stroke patients: predictors and prognostic implicationsA Zangerle, S Kiechl, M Spiegel, et al.
Pageof 26

Showing results (231-240 of 258) with videos related to

Sort By:
Pageof 26
European Journal of Neurology|October 14, 2006
Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's diseaseM Horstink, E Tolosa, U Bonuccelli, et al.
Der Nervenarzt|February 10, 2015
[Predictors of mental and physical quality of life in Huntington's disease]F Brugger, C Hepperger, E-M Hametner, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 22, 1998
What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study GroupW Poewe, G Deuschl, A Nebe, et al.
European Journal of Neurology|October 14, 2006
Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's diseaseM Horstink, E Tolosa, U Bonuccelli, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 7, 1998
Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examinationG K Wenning, I Litvan, J Jankovic, et al.
Stroke|October 7, 2000
A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after strokeA M Bakheit, A F Thilmann, A B Ward, et al.
Journal of Neurochemistry|August 25, 2001
Temporal and spatial profile of caspase 8 expression and proteolysis after experimental traumatic brain injuryR Beer, G Franz, S Krajewski, et al.
Parkinsonism & Related Disorders|November 29, 2016
Sniffing the diagnosis: Olfactory testing in neurodegenerative parkinsonismF Krismer, B Pinter, C Mueller, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 16, 2000
Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging studyN Hyman, M Barnes, B Bhakta, et al.
Neurology|January 4, 2007
Recanalization after thrombolysis in stroke patients: predictors and prognostic implicationsA Zangerle, S Kiechl, M Spiegel, et al.
Pageof 26